Teenagers' blood being sold for £6,200 a shot
Founder claims treatment is 'like plastic surgery from the inside out'
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Transfusions of teenage blood are being sold for £6,200 a shot, with a US company claiming it may have anti-ageing properties.
More than 100 people have undergone a clinical trial at Ambrosia, a start-up in San Francisco founded by Stanford-trained doctor Jesse Karmazin, in which they are injected with two and a half litres of plasma, the liquid portion of blood which remains after other cells are removed.
The early results have been encouraging, with Mr Karmazin telling The Sunday Times the treatment is "like plastic surgery from the inside out."
“It could help improve things such as appearance or diabetes or heart function or memory," he said. "These are all the aspects of ageing that have a common cause.
“I’m not really in the camp of saying this will provide immortality but I think it comes pretty close, essentially.”
However, researchers have warned the procedure is unproven and the trial is unlikely to provide much in the way of clinical evidence to support Mr Karmazin's claims.
It has also been criticised for failing to include a placebo group and for having participants pay to take part in the trial.
While the study is based on research suggesting old mice injected with plasma from young mice have improved memory and ability to learn, the author of that 2014 study has said there is "just no clinical evidence" the treatment would be beneficial.
"You're basically abusing people's trust and the public excitement around this," neuroscientist Tony Wyss-Coray told Science Mag last year.
In Ambrosia's trial, surplus blood is bought from blood banks, ideally from teenage donors, before the plasma is separated.
The two and a half litre transfusion, a mix from several donors, is then injected into the participants, who had a median age of 60.
Mr Kamazin claimed patients had already been seen to "look better after just one treatment."
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments